Reducing Cancer Health Disparities in Detroit

减少底特律的癌症健康差异

• 批准号: 10684276
• 负责人: ELISABETH IIJAS HEATH
• 金额: $ 97.38万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10684276
• 关键词: Acceleration; African American; African American population; Area; Automobile Driving; Awareness; Behavioral; Biological; Cancer Biology; Cancer Burden; Cancer Patient; Censuses; Cities; Clinical; Clinical Trials; Communities; Community Outreach; Comprehensive Cancer Center; County; Development; Disease; Disparity; Ensure; Environment; Equity; Evaluation; Face; Foundations; Funding; Future; Genetic; Genetic Medicine; Genomics; Guidelines; Home; Household; Immune; Immune checkpoint inhibitor; Immunotherapy; Income; Individual; Malignant Neoplasms; Malignant neoplasm of lung; Medically Underserved Area; Mentors; Michigan; Minority Groups; Modeling; Molecular; New Agents; Outcome; Participant; Patients; Population; Population Heterogeneity; Poverty; Quality of life; Race; Reduce health disparities; Reporting; Research; Research Personnel; Research Project Grants; Scientist; Specialized Program of Research Excellence; Structure; Translating; Translational Research; Translations; Tumor Markers; Underserved Population; United States Health Resources and Services Administration; Universities; Work; cancer health disparity; cancer prevention; cancer site; cancer therapy; clinical application; community engagement; disparity reduction; health disparity; high risk; immune-related adverse events; improved; innovation; member; metropolitan; novel marker; participant enrollment; patient engagement; patient population; precision medicine; programs; racial disparity; racial diversity; recruit; response; side effect; standard care; standard of care; treatment response; tumor

Overall Program Summary This application for Feasibility and Planning Studies of a P20 Specialized Program of Research Excellence (SPORE) to Investigate Cancer Health Disparities will address racial disparities in metropolitan Detroit, a uniquely important underserved population where great cancer disparities exist. The application includes two scientific projects focused on treatment with immune checkpoint inhibitors (ICIs) now being used in the standard of care setting for lung cancer, an Administrative Core, a Biospecimen Core, a Patient and Community Engagement Core, and a Developmental Research Program. The decision to use ICIs relies heavily on prior treatment response and imperfect tumor biomarkers, and immune-related adverse events (irAEs) dictate continued therapy, and ultimately outcomes, yet little is known about what factors drive disease course in racially diverse populations. The Overall Aim 1 of this Program is to accelerate translational research to reduce health disparities in lung cancer outcomes by: a) characterizing race-specific immune profiles with respect to the tumor environment and host genetic background to determine their contribution to response to ICIs (Project 1); and b) characterizing patient-reported side effects, quality of life, and irAEs in a racially diverse group of lung cancer patients and identifying the individual, behavioral, molecular/genetic and disease-specific determinants of these end points (Project 2). The Overall Aim 2 is to strengthen the existing programmatic structure to encourage translational research into the biology of cancer health disparities, achieve full P50 SPORE funding, and ultimately reduce cancer health disparities by: a) expanding our Cancer Biology of Health Disparities initiative, facilitating use of biospecimens from KCI's racially diverse population, and funding Developmental Research Projects; b) mentoring investigators in cancer health disparities; and c) expanding our community outreach and engagement efforts through a robust Patient and Community Engagement Core (PCEC) to support recruitment and retention of diverse study participants and dissemination of research project progress and findings to participants and lay audiences. This P20 application will enable clinical, basic and population scientists to translate relevant, high-impact scientific discoveries in diverse patients to reduce racial disparities in cancer outcomes, moving towards a more race-inclusive, equity-focused precision medicine approach to cancer treatment and prevention.

总体方案摘要 本申请为研究卓越的P20专业计划的可行性和规划研究 （SPORE）调查癌症健康差异将解决底特律大都市的种族差异 在癌症差异很大的地区，这是一个非常重要的缺医少药的人群。该应用程序包括两个 科学项目专注于免疫检查点抑制剂（ICI）治疗，目前正在标准中使用 肺癌护理环境，管理核心，生物标本核心，患者和社区 参与核心和发展研究计划。使用ICI的决定在很大程度上依赖于先前的 治疗反应和不完善的肿瘤生物标志物以及免疫相关不良事件（irAE）决定了 持续的治疗，最终的结果，但很少有人知道是什么因素驱动疾病的过程中，种族 不同的人群。该计划的总体目标1是加速转化研究，以减少健康 肺癌结果的差异：a）表征与肿瘤相关的种族特异性免疫谱 环境和宿主遗传背景，以确定它们对ICI反应的贡献（项目1）;和B） 描述不同种族肺癌患者报告的副作用、生活质量和irAE 患者和确定这些个体，行为，分子/遗传和疾病特异性决定因素 终点（项目2）。总体目标2是加强现有的方案结构，以鼓励 转化研究到癌症健康差异的生物学，实现完整的P50孢子资金， 通过以下方式最终减少癌症健康差异：a）扩大我们的癌症健康差异生物学倡议， 促进使用KCI种族多样性人口的生物标本，并资助发展研究 项目; B）指导癌症健康差异的研究人员;以及c）扩大我们的社区外展， 通过强大的患者和社区参与核心（PCEC）来支持招募 和留住不同的研究参与者，并传播研究项目的进展和结果， 参与者和观众。这一P20应用将使临床、基础和人口科学家能够 在不同的患者中翻译相关的，高影响力的科学发现，以减少癌症的种族差异 结果，朝着更具种族包容性，以公平为中心的癌症精准医学方法迈进 治疗和预防。